56 results about "Ventricular contraction" patented technology

Methods and systems for automated electrocardiogram (ECG) analysis using neural networks, enhancing the accuracy of beat-by-beat cardiac monitoring. The system utilizes a Generative Adversarial Network (GAN) and beat classifiers to analyze ECG data and detect conditions various beast properties of an ECG at a discrete level. Additional neural networks may be trained to detect beat based conditions such as premature atrial contractions (PACs) and premature ventricular contractions (PVCs). The GAN generates realistic ECG beats, while classifiers detect abnormalities. Additional transformers may be trained to detect rhythm based conditions such as AFib and Aflutter. Methods and Systems support real-time cardiac health insights and integrates with ECG devices for continuous monitoring, offering a robust solution for improving diagnostic accuracy.

A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.

A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.

Methods and systems for automated electrocardiogram (ECG) analysis using neural networks, enhancing the accuracy of beat-by-beat cardiac monitoring. The system utilizes a Generative Adversarial Network (GAN) and beat classifiers to analyze ECG data and detect conditions various beast properties of an ECG at a discrete level. Additional neural networks may be trained to detect beat based conditions such as premature atrial contractions (PACs) and premature ventricular contractions (PVCs). The GAN generates realistic ECG beats, while classifiers detect abnormalities. Additional transformers may be trained to detect rhythm based conditions such as AFib and Aflutter. Methods and Systems support real-time cardiac health insights and integrates with ECG devices for continuous monitoring, offering a robust solution for improving diagnostic accuracy.

According to the atrial fibrillation recognition method based on multi-feature fusion, multiple feature extraction task branches are constructed in the same deep learning model, the RR interval features, the P-wave features and the electrocardio waveform morphological features are extracted synchronously and parallelly, and the problems of feature loss and time sequence mismatching caused by multi-step processing are avoided; the model captures RR interval irregularity in a time domain, captures P wave missing and baseline f wave features in a morphological domain, forms a rhythm-morphological-frequency spectrum triple feature system, realizes more stable identification of atrial fibrillation, can effectively distinguish similar expressions of atrial fibrillation and ventricular premature, atrial premature, sinus arrhythmia and the like based on a coordination mechanism of appetite and morphological domain, and improves the accuracy of atrial fibrillation identification. And the identification rate of the atrial fibrillation signal in the electrocardiogram data can be effectively improved.

Techniques for triggering the storage or transmission of cardiac electrogram (EGM) signals associated with a premature ventricular contractions (PVC) include sensing a cardiac EGM signal of a patient via a plurality of electrodes, detecting a premature ventricular contraction (PVC) within the cardiac EGM signal, determining whether PVC storage criteria is met, in response to a determination that the PVC storage criteria is met, storing a portion of the cardiac EGM signal associated with the PVC, and in response to a determination that the PVC storage criteria is not met, eschewing storing the portion of the cardiac EGM signal associated with the PVC.

A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.

Techniques for determining whether a ventricular depolarization is a premature ventricular contraction (PVC) depolarization may include processing circuitry of a medical system identifying an interval from a maximum slope point to a minimum slope point for each of a plurality of ventricular depolarizations and, for each of the plurality of ventricular depolarizations as a current ventricular depolarization, determining that the intervals from the maximum slope point to the minimum slope point for the current ventricular depolarization, a preceding adjacent ventricular depolarization of the plurality of ventricular depolarizations, and a subsequent adjacent ventricular depolarization of the plurality of ventricular depolarizations satisfy one or more slope criteria. The processing circuitry determines that the current ventricular depolarization is a PVC depolarization based on the intervals from the maximum slope point to the minimum slope point satisfying the one or more slope criteria.

An implantable circulatory support system, configured to connect a ventricular chamber of a heart, including a valveless displacement blood pump, a deformable polymeric flow cannula, a pair of male and female fasteners, a coupler, a driveline assembly, and a co-pulsatile driver. Forward and backward flow communication between the blood pump and the heart chamber is accomplished using the present flow cannula invention which is anastomosed to the heart chamber in a sutureless manner. When providing circulatory support, the co-pulsatile driver ejects blood out of the blood pump during systolic ventricular contraction and fills the blood pump with blood during diastolic ventricular relaxation.

Implantable medical device for stimulating a heart includes a proximal electrode pole, and first and second distal electrode poles. During operation, the device performs: a) detecting an intrinsic atrial contraction of the heart; b) detecting an intrinsic ventricular contraction of the heart; c) determining a first intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction detected with the first distal electrode pole; and determining a second intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and iii) the intrinsic ventricular contraction detected with the second distal electrode pole; d) setting a stimulated atrioventricular conduction time for stimulating the ventricle of the heart with the first and / or second distal electrode poles, the stimulated atrioventricular conduction time being shorter than the shorter of the first and second intrinsic atrioventricular conduction times.

Techniques for determining whether a ventricular depolarization is a premature ventricular contraction (PVC) depolarization can include processing circuitry of a medical system that identifies an interval from a maximum slope point to a minimum slope point of each of a plurality of ventricular depolarizations and, for each of the plurality of ventricular depolarizations as a current ventricular depolarization, determines that an interval from a maximum slope point to a minimum slope point of the current ventricular depolarization, a previous adjacent ventricular depolarization of the plurality of ventricular depolarizations, and a subsequent adjacent ventricular depolarization of the plurality of ventricular depolarizations satisfies one or more slope criteria. The processing circuitry determines, based on the interval from the maximum slope point to the minimum slope point that satisfies the one or more slope criteria, that the current ventricular depolarization is a PVC depolarization.

This document discusses, among other things, systems and methods to receive cardiac electrical information of a subject, detect a premature ventricular contraction (PVC) event in a first detection window using the received cardiac electrical information, determine a count of detected PVC events in the first detection window, remove cardiac electrical information associated with the detected PVC event from the first detection window based on the determined count of detected PVC events, and detect an indication of atrial fibrillation of the subject for the first detection window using remaining cardiac electrical information in the first detection window.

The invention relates to a device usable with a valve disposed between the atrium and the ventricle of a heart, the valve having a first leaflet (S) and at least one opposing leaflet (A, P). The apparatus includes an enhancer (700) that includes a flexible pouch (710) and an anchor (780). The pouch has an outer surface, an interior, an exterior, and a downstream opening providing fluid communication between the interior and the exterior of the pouch. The anchor is coupled to the pouch and is configured to anchor the pouch to a lip of the first leaflet by anchoring the anchor to the first leaflet. The anchoring is such that the downstream opening opens into the ventricle. In response to ventricular contraction, the pouch is inflated through the downstream opening and the outer surface engages against the opposing leaflets.

The present invention discloses a LVAD multi-objective optimization method, system, device, storage medium and product, the method comprising constructing a 3D model of ventricles and aorta, constructing a ventricular motion function; adding an LVAD structure to the 3D model of ventricles and aorta according to each set of sample parameters, obtaining multiple 3D models of ventricles and aorta containing LVAD structures; meshing the 3D model of ventricles and aorta containing LVAD structures to generate a network model; based on the ventricular motion function, controlling ventricular contraction and rotational motion, calculating platelet shear stress history and platelet retention time; constructing a Kriging model according to the platelet shear stress history and platelet retention time of each set of sample parameters; and using an optimization algorithm to find the optimal set of structural parameters from the prediction results of the Kriging model. The present invention uses multiple structural parameters as optimization variables, effectively solving the problem that thrombosis cannot be effectively reduced after LVAD implantation.

Techniques for triggering storage or transmission of electrogram (EGM) signals associated with premature ventricular contractions (PVCs) include sensing cardiac EGM signals of a patient with a plurality of electrodes, detecting a premature ventricular contraction (PVC) within the cardiac EGM signals, determining whether PVC storage criteria are met, storing a portion of the cardiac EGM signals associated with the PVC in response to a determination that the PVC storage criteria are met, and refraining from storing the portion of the cardiac EGM signals associated with the PVC in response to a determination that the PVC storage criteria are not met.

The invention relates to a leadless heart sensing and pace-making system based on ultrasonic energy transmission. The leadless heart sensing and pace-making system comprises a miniature ultrasonic probe and a leadless pace-making structure capable of being implanted into a plurality of cavities of a human body, the pace-making structure is a micro structure without an energy supply system; the probe comprises a microprocessor integrated with an intelligent agent, a sensing module, a transmitting device used for transmitting energy pulses and an energy supply device. The sensing module is used for acquiring a heart atrioventricular contraction ultrasonic image in real time, processing the heart atrioventricular contraction ultrasonic image through an intelligent agent in the microprocessor and reasoning to determine whether pace-making pulse distribution of a pace-making structure in at least one cavity needs to be started or not; and if so, sending a pace-making instruction with an energy pulse through a transmitting device to which the pace-making structure of the corresponding chamber belongs. The pace-making structure in the system can be placed in each chamber of the heart in a miniaturized manner, so that the occupied space is small, and the stability is ensured. More importantly, the system can realize heart sensing and pace-making at the same time, and the purpose of pace-making according to needs is achieved.

The invention belongs to the technical field of cardiac contraction auxiliary devices, and relates to a light actuator and a preparation method thereof. The optical actuator comprises a sawtooth silica gel film, a silica gel line, an optical fiber and a liquid crystal elastomer fiber. The preparation method comprises the following steps: (a) adding a pore-forming line with the same shape and size as a silica gel line into a mold cavity with the same shape and size as a sawtooth silica gel film, pouring uncured first silica gel into the mold cavity, and sequentially carrying out heating curing, demolding and pore-forming line extraction to obtain a sawtooth silica gel film with through holes; (b) pouring uncured second silica gel into the through holes of the sawtooth silica gel membrane with the through holes, inserting an optical fiber into the rear end of each through hole, and heating and curing to obtain a semi-finished product consisting of the sawtooth silica gel membrane, the silica gel line and the optical fibers; and (c) connecting the liquid crystal elastomer fiber with the front end of the sawtooth silica gel film to obtain the light actuator. The light actuator can be aligned with the ventricular contraction frequency and time, and the requirement for assisting in cardiac contraction is met.

A method includes detecting that a first premature ventricular contraction (PVC) episode occurred within a first length of electrocardiogram (ECG) data. The method further includes recording the first length of ECG data to memory in response to the detecting. A second PVC episode is determined to have occurred after the first PVC episode and within a second length of ECG data, and the second PVC episode is determined to be either a first type of PVC episode or a second type of PVC episode. The method further includes determining whether to either overwrite the first length of ECG data or to separately record the second length of ECG data to the memory based, at least in part, on the determining that the second PVC episode is the first type of PVC episode or the second type of PVC episode.

Brugada syndrome and related forms of ion channelopathies, including ventricular asynchrony of contraction, originate in the region near the His bundle or para-Hisian regions of the heart. Manifestations of Brugada syndrome can be corrected by delivering endocardial electrical stimulation coincident to the activation wave front propagated from the atrioventricular (AV) node early enough to compensate for the conduction problems that start in those regions. The stimulation can be delivered in multiple modes and can include waveforms of the same polarity delivered to a site within the region near the His bundle or para-Hisian regions of the heart associated with a low cardiac electrical asynchrony level or can include at least two single-phased superimposed waveforms of opposite polarity delivered through a pair of pacing electrodes relative to a reference electrode, which can be delivered to any site within the region near the His bundle or para-Hisian regions.

Systems and methods for managing heart failure are described. The system receives physiological information including a first HS signal corresponding to paced ventricular contractions and a second HS signal corresponding to intrinsic ventricular contractions. The system detects worsening heart failure (WHF) using the received physiological information. A signal analyzer circuit can generate a paced HS metric from the first HS signal and a sensed HS metric from the second HS signal, and determine a concordance indicator between the paced and the sensed HS metrics. In response to the detected WHF, the system can use the concordance indicator to generate a therapy adjustment indicator for adjusting electrostimulation therapy, or a worsening cardiac contractility indicator indicating the detected WHF is attributed to degrading myocardial contractility.

The present invention belongs to the technical field of cardiac contraction assist devices and relates to a photoactuator and its preparation method. The photoactuator comprises a serrated silicone membrane, a silicone wire, an optical fiber, and a liquid crystal elastomer fiber. The preparation method comprises the following steps: (a) inserting a pore-forming wire of the same shape and size as the silicone wire into a mold cavity of the same shape and size as the serrated silicone membrane, pouring uncured first silicone into the cavity, and then heating and curing, demolding, and removing the pore-forming wire to obtain a serrated silicone membrane with through holes; (b) pouring uncured second silicone into the through holes of the serrated silicone membrane with through holes, simultaneously inserting an optical fiber into the rear end of each through hole, and then heating and curing to obtain a semi-finished product consisting of the serrated silicone membrane, silicone wire, and optical fiber; and (c) connecting the liquid crystal elastomer fiber to the front end of the serrated silicone membrane to obtain the photoactuator. The photoactuator of the present invention can align with the frequency and timing of ventricular contraction, meeting the requirements of assisting cardiac contraction.

A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.

A non-transvenous implantable cardioverter defibrillator device comprises a generator device comprising a processing circuitry and a shock generation circuitry, and at least one lead comprising a shock electrode for emitting electrical shock pulses externally to a patient's heart. The processing circuitry is configured to identify a sensed ventricular contraction event in a sensed electrocardiogram signal or said processing circuitry is configured to control said shock generation circuitry to generate at least one conditioning pulse for emission by said shock electrode to cause an induced ventricular contraction event. The processing circuitry is further configured to control said shock generation circuitry to generate a fibrillation pulse for emission by said shock electrode at a delay time after said sensed or induced ventricular contraction event in order to induce a cardiac fibrillation state.

The invention belongs to the technical field of medical treatment, and provides a method for predicting long-term relapse of early ventricular ablation based on intracardiac potential spectrums.The method comprises the steps that intracardiac bipolar potentials before and after ablation are collected at a successful ablation target; performing fast Fourier transform on the potential signal to obtain a power frequency spectrum of the potential signal; in the 0-200Hz analysis frequency band, calculating the area under the curve of the 50-200Hz high-frequency component as the integral of the high-frequency component, and calculating the ratio of the integral of the high-frequency component to the total integral of the frequency spectrum to obtain the integral ratio of the high-frequency component; the ratio before ablation and after ablation is calculated respectively, the change value of the ratio is calculated and determined through ROC curve analysis, and the change value exceeding a threshold value is used as a critical value for predicting the low recurrence risk after ablation, time-domain signal analysis is innovated into frequency-domain quantitative analysis, an objective and accurate new index is provided for evaluating the ablation injury quality and predicting prognosis, and the risk of low recurrence after ablation is predicted. The device is especially suitable for ventricular arrhythmia of aorta root origin.

Disclosed are systems, methods, and computer program product for cardiac event risk assessment including for assessing future cardiac risk for a patient. The disclosed systems can include a wearable cardiac sensing device configured to be removably, bodily-attached to the patient, configured to sense signals from a patient and provide the digitized to a processor configured to determine cardiac event risk assessment. In some embodiments, cardiac event risk assessment can be determined based on a cardiovibration classifier, counts or burdens associated with premature ventricular contractions (PVC) patterns, and multi-focal PVCs.

The invention belongs to the technical field of biological medicine, and particularly relates to a traditional Chinese medicine composition for preventing or treating premature beat and a preparation method, application and a product thereof. The traditional Chinese medicine composition for preventing or treating premature beat provided by the invention consists of dalbergia wood, salvia miltiorrhiza, fried spina date seed, platycladi seed, ginseng, radix sophorae flavescentis, lalang grass rhizome and nacre mother of pearl. The traditional Chinese medicine composition provided by the invention can delay the occurrence of premature ventricular contraction, ventricular tachycardia and ventricular fibrillation, can be used for preventing or treating premature contraction, can improve druggability, can relieve the burden of a patient, can effectively improve symptoms, and has a relatively good curative effect on treating heart blood stasis and restless premature contraction by starting from regulating blood vessels and tranquilizing heart and mind based on the view of integration of veins and mind. The traditional Chinese medicine solves the problems that the traditional Chinese medicine for treating premature beat is large in dosage and poor in druggability, the economic burden of a patient is increased after long-term taking, and the effect on some syndromes is not ideal.

The invention discloses an application of a traditional Chinese medicine composition in a medicine for preventing and treating ventricular arrhythmia. The traditional Chinese medicine composition comprises ginseng, lucid ganoderma, safflower, musk, calculus bovis, bear gall, pearl, venenum bufonis, radix aconiti carmichaeli and borneol. Wherein the mass ratio of the ginseng, the pearl and the lucid ganoderma is 11%-70% respectively and independently. According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compatibility of all the components, the symptoms of ventricular arrhythmia can be effectively relieved from multiple aspects through at least one of ventricular premature beat, ventricular tachycardia, ventricular fibrillation occurrence time, QTc, PR interval and QRS wave group time which are improved through sleep regulation, and the progress of a disease course is blocked. The traditional Chinese medicine composition is controllable in quality, convenient for standardized production, safe and reliable in prescription and free of toxic and side effects on human bodies.

A method includes detecting that a first premature ventricular contraction (PVC) episode occurred within a first length of electrocardiogram (ECG) data. The method further includes recording the first length of ECG data to memory in response to the detecting. A second PVC episode is determined to have occurred after the first PVC episode and within a second length of ECG data, and the second PVC episode is determined to be either a first type of PVC episode or a second type of PVC episode. The method further includes determining whether to either overwrite the first length of ECG data or to separately record the second length of ECG data to the memory based, at least in part, on the determining that the second PVC episode is the first type of PVC episode or the second type of PVC episode.

The invention relates to an ECG-gated CAG contrast agent discrete optimized injection method, which comprises the following steps: acquiring stable ECG signals, and acquiring and monitoring ECG by adopting a chest lead mode; in order to realize real-time gating of discontinuous injection of the contrast agent in a single cardiac cycle, the method comprises the following steps of: detecting the cardiac cycle in real time, namely detecting a phase point at the beginning of a ventricular systolic period; taking the time interval of the starting time phase points of the two ventricular systolic periods as a single cardiac cycle, not injecting a contrast agent from the starting time phase point of the first ventricular systolic period to the absolute time phase delta millisecond in the single cardiac cycle, and injecting the contrast agent from the absolute time phase delta millisecond to the starting time phase point of the second ventricular systolic period; based on injection of the ECG gated contrast agent in the single cardiac cycle, the contrast agent injection time is determined, the contrast agent is injected, and gating of the whole contrast agent injection process is achieved.

A medical device system includes an implantable medical device configured to sense cardiac electrogram data and processing circuitry. The processing circuitry is configured to identify a premature ventricular contraction event within the cardiac electrogram data. The processing circuitry is configured to determine, for at least one or more cardiac cycles associated with the premature ventricular contraction event, one or more periodic repolarization dynamics metrics based on the cardiac electrogram data. The processing circuitry is configured to determine, for at least the one or more cardiac cycles associated with the premature ventricular contraction event, one or more turbulence metrics based on the one or more periodic repolarization dynamics metrics. The processing circuitry is configured to determine whether to provide an indication of at least one of sudden cardiac arrest or ventricular tachyarrhythmia based on the one or more periodic repolarization dynamics metrics and the one or more turbulence metrics.